Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 33,600 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Conditions
Solid Tumor
Interventions
Oratecan
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
VEXAS Syndrome
Interventions
Momelotinib, Glucocorticoids, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Saraland, Alabama • Tucson, Arizona • Encino, California + 22 more
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
Momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Whittier, California • Tupelo, Mississippi + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of ARRY-300 in Healthy Subjects

NCT00828165
Conditions
Healthy
Interventions
ARRY-300, MEK inhibitor; oral, Placebo
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Conditions
Adenovirus Infections
Interventions
cidofovir, Brincidofovir
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Conditions
Relapsed/Refractory Small Cell Lung Cancer
Interventions
BMS-986525, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
22
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
Conditions
Crohn's Disease
Interventions
brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Fairhope, Alabama • Tucson, Arizona • Escondido, California + 20 more
Conditions
Obesity, Overweight, Obstructive Sleep Apnoea
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more
Conditions
Epilepsy
Interventions
ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
Interventions
Exa-cel
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 4 more
Conditions
Vaping, E-Cig Use
Interventions
cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Lexington, Kentucky • Boston, Massachusetts • Rochester, New York + 2 more
Conditions
Bacterial Conjunctivitis
Interventions
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Month and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Low-grade Upper Tract Urothelial Carcinoma
Interventions
Nadofaragene Firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 4 more
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Enrolling by invitation Not applicable Interventional

MR-Guided Cryoablation of Prostate Bed Recurrences

NCT01727284
Conditions
Prostate Tumors
Interventions
MR-guided cryoablation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY001-001 in Healthy Volunteers

NCT06448247
Conditions
Healthy
Interventions
SPY001-001, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Liver Failure, Carcinoma, Hepatocellular
Interventions
Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
Observational study with no interventions
Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
La Jolla, California